Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/22/2023
Locations: Om Research LLC, Lancaster, California +11 locations
Conditions: Primary Biliary Cholangitis
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/22/2023
Locations: The Institute for Liver Health II dba Arizona Liver Health, Chandler, Arizona +11 locations
Conditions: Primary Biliary Cholangitis
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Southern California Research Center, Coronado, California +58 locations
Conditions: Primary Biliary Cholangitis, PBC
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Recruiting
The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: UA Thomas D. Boyer Liver Institute, Tucson, Arizona +127 locations
Conditions: Primary Biliary Cholangitis, Liver Stiffness
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
Recruiting
This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/16/2023
Locations: Southern California Research Center, Coronado, California +20 locations
Conditions: Primary Biliary Cholangitis
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Recruiting
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/06/2023
Locations: Zydus US007, Birmingham, Alabama +30 locations
Conditions: Primary Biliary Cholangitis
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/13/2023
Locations: The Institute of Liver Health dba Arizona Liver Health, Chandler, Arizona +17 locations
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment